Oligonucleotide Synthesis Market Research Report Information By Product (Oligonucleotide, Reagents and Equipment), By Type (Custom Oligos and Predesigned Oligos), By Applications (Therapeutic Applications, Diagnostics, Research, and Others), By End Users (Academic Research Institutes, Pharmaceutical and Biotechnology Companies, Diagnostic Laboratories, and Others), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2032

Global Oligonucleotide Synthesis Market Overview

The Oligonucleotide Synthesis Market Size was valued at USD 10.47 billion in 2023 and is projected to grow from USD 12.38 Billion in 2024 to USD 44.32 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 15.23% during the forecast period (2024 - 2032). Government grants are getting more money, and the rising prevalence of chronic and rare diseases is the key market driver enhancing market growth.

In November 2023, Twist Bioscience Corporation (NASDAQ: TWST), a company that empowers customers to achieve success by providing high-quality synthetic DNA through its silicon platform, introduced Twist Express Genes, a new, industry-leading gene synthesis service with a five- to seven-business-day turnaround time. Twist utilizes its silicon-based DNA synthesis platform, expertise, software, honed processes, and the expanded layout of its Wilsonville facility to deliver clonal genes and gene fragments at scale and with rapid turnaround times, thereby leveraging its ability to miniaturize the chemical reaction to create DNA. Twist will implement dynamic pricing for Express Genes, charging a premium for speed that is contingent upon market demand and manufacturing capacity. Twist's ecommerce platform will enable customers to place orders for Express Genes. The length of Twist Express genes ranges from 0.3 to 5.0 kb. As with standard speed Twist Clonal Genes, Twist Express Genes are NGS sequence-verified as one hundred percent accurate, and orders of any size, big or small, can be filled as a result of the scale facilitated by Twist's platform. Customers can proceed directly to experimentation by cloning Twist Express Genes into catalog vectors or custom vectors. They can also be delivered in the preferred delivery format of the consumer, such as a tube or plate.

In October 2023, Waters Corporation has introduced OligoWorks SPE (solid-phase extraction) kits and components to enhance the preparation of samples for LC-MS-based bioanalytical quantitation of therapeutic oligonucleotides. The oligonucleotide recovery from biofluids can now be enhanced by up to a twofold over competing products for pharma and biopharma companies that are developing oligonucleotide therapeutics, as well as the Contract Research Organizations (CROs) that support them. The packages provide increased LC-MS sensitivity and reproducibility, which reduces the necessity for repeat experiments and enables lower limits of quantitation. The pipeline for oligonucleotide therapeutics is expanding at a rapid pace, with 13 FDA-approved oligonucleotide therapeutics currently in circulation and over 500 more in the pipeline. Although efficacious, these highly modified oligonucleotides are difficult to precisely quantify during dosing, metabolism, and tissue distribution studies. OligoWorks SPE kits also employ an innovative, enzyme-enhanced, and detergent-free sample pretreatment that enables direct injection LC-MS analysis and lower limits of quantitation. This pretreatment reduces the number of rinsing steps and enhances mass spectrometer compatibility. Additionally, they can be entirely automated to enhance productivity or to assist scientists in reclaiming time by minimizing manual steps and oversight.

Oligonucleotide Synthesis Market Trends

• Rising prevalence of chronic and rare diseases boosts the market growth

Due to factors like the rising prevalence of chronic and rare diseases, the growing use of oligonucleotides in drug development, and the increase in product launches, the therapeutics segment is anticipated to experience significant growth in the oligonucleotide synthesis market over the forecast period. Therapeutics are known as oligonucleotide therapeutics target RNA or protein with antisense oligonucleotides or small interfering RNAs (siRNAs). Decoys that target transcription factors to prevent transcription, control the expression of complementary microRNAs (miRNAs) to particular mRNAs, and restrict the translation of specific mRNAs into proteins are all examples of oligonucleotide therapies. For instance, oligonucleotide therapeutics is one of the most flexible platforms for developing drugs for rare diseases, according to a February 2022 article in Future Medicine.

The focus of the expanding company on implementing different business strategies, such as partnerships, financing, and others, is also assisting in the expansion of the market. As an illustration, Ceptur Therapeutics, Inc. RNA therapeutics based on proprietary U1 adaptor technology, a bivalent oligonucleotide that engages sequence-specific mRNA and U1 small nuclear ribonuclear protein, have successfully raised USD 75 million in a Series-A financing round led by venBio Partners and Qiming Venture Partners USA. A common intracellular device that controls transcription and splicing is the U1 small nuclear ribonuclear protein. Synthetic oligonucleotides that interact with U1 snRNP allow for the highly targeted regulation of mRNA by co-opting the important transcriptome regulator has enhanced the Oligonucleotide Synthesis market CAGR across the globe in recent years.

Oligonucleotide Synthesis Market Segment Insights

Oligonucleotide Synthesis Type Insights

Based on type, the Oligonucleotide Synthesis market segmentation includes Oligonucleotide, Reagents and Equipment. The Oligonucleotide segment held the majority share in 2022 contribution concerning the Oligonucleotide Synthesis market revenue. The unresectable pancreatic cancer drug STNM01 is being developed by TME Therapeutics and is currently the subject of a Phase-I clinical trial. In addition, Nitto Biopharma is testing ND-L02-s0201 for idiopathic pulmonary fibrosis (IPF) as part of a Phase-II study. Amondys 45 (cashmere), an injection, has been approved by the USFDA to treat Duchenne muscular dystrophy (DMD) in people with a verified DMD gene mutation. Additionally, several businesses are creating oligonucleotide therapeutics, which are anticipated to see increased adoption in the pharmaceutical and biotechnology sectors, supporting the market expansion.

Oligonucleotide Synthesis Type Insights

Based on type, the Oligonucleotide Synthesis market segmentation includes Custom Oligos and Predesigned Oligos. The metal segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. This is due to the increasing preference for metal implants due to their high corrosion resistance. Metal materials such as titanium alloys and stainless steel are extensively utilized in metal implants in spine surgeries. Many healthcare professionals, including surgeons, doctors, and clinicians, increasingly prefer metal implants due to their high corrosion resistance. Moreover, the use of metal implants entails considerably lower costs than polymers. Hence, rising applications of metal material implants for Oligonucleotide Synthesis positively impact the market growth.

Oligonucleotide Synthesis Application Insights

Applications have bifurcated the Oligonucleotide Synthesis market data into Therapeutic Applications, Diagnostics, Research, and Others. The Therapeutic Applications segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period 2024-2032 due to increased research into therapeutic applications.

Figure 1 Oligonucleotide Synthesis Market, by Product, 2022 & 2030 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Oligonucleotide Synthesis End User Insights

Based on end users, the  oligonucleotide synthesis industry has been segmented into Academic Research Institutes, Pharmaceutical and Biotechnology Companies, Diagnostic Laboratories, and Others. Multispecialty hospitals held the largest segment share in 2022 due to a large number of inpatient and outpatient hospital visits and the high demand for oligonucleotide medications to meet the rising demand from patients with rare diseases, neurological diseases disorders, and infectious diseases.

Oligonucleotide Synthesis Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North America Oligonucleotide Synthesis market accounted for USD 0.88 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. The rising incidence of chronic and rare diseases among the population, rising corporate R&D spending, and the presence of major market players contribute to market growth.

Over 1.9 million new cancer cases are anticipated to be diagnosed in the United States in 2022, according to Cancer Facts and Figures 2022. Additionally, according to statistics for 2022 provided by Breastcancer.org, there will likely be 51,400 new cases of non-invasive (in situ) breast cancer and 287,850 new cases of invasive breast cancer, respectively. The rising incidence of cancer among the populace increases the demand for cutting-edge therapeutics, increasing the price of oligonucleotide therapeutics and accelerating market expansion. Approximately 2.9 million people in Canada had diabetes in 2021, according to IDF statistics for 2022. This figure is anticipated to reach 3.2 million and 3.4 million by 2030 and 2045, respectively. Because antisense oligonucleotides can lower the expression of disease-causing genes at the RNA and protein levels, they are increasingly in demand as the country's diabetic population is expected to rise. Throughout the projection period, this is expected to accelerate market growth.

Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE BY REGION 2022 (%)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe’s Oligonucleotide Synthesis market accounts for the second-largest market share Market expansion is anticipated to be fueled by rising regional product launches and drug development. Further, the Germany Oligonucleotide Synthesis market held the largest market share, and the UK Oligonucleotide Synthesis market was the fastest-growing market in the European region.

The Asia-Pacific Oligonucleotide Synthesis Market is expected to grow at the fastest CAGR from 2024 to 2032. The market is expected to grow due to factors including the rising incidence of cancer, increased product launches and approvals, increased company clinical trial activities, and a growing company emphasis on investing in the oligonucleotides business. Moreover, China’s Oligonucleotide Synthesis market held the largest market share, and the India Oligonucleotide Synthesis market was the fastest-growing market in the Asia-Pacific region.

Oligonucleotide Synthesis Key Market Players & Competitive Insights

Major market players are spending much on R&D to increase their product lines, which will help the Oligonucleotide Synthesis market grow even more. Market participants are also taking various strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Oligonucleotide Synthesis industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

Manufacturing locally to reduce operating costs is one of the primary business strategies manufacturers adopt in the Oligonucleotide Synthesis industry to benefit clients and expand the market sector. The Oligonucleotide Synthesis industry has provided medicine with some of the most significant benefits in recent years. The Oligonucleotide Synthesis markets’ major players such as Thermo Fisher Scientific Inc., Adtbio Merck - Co. Inc., Bio-Synthesis Inc., Eurofins Genomics, GE Healthcare, Horizon Discovery Ltd, Agilent Technologies, Genscript, Kaneka Eurogentec SA, and others are working on expanding the market demand by investing in research and development activities.

Thermo Fisher Scientific Inc. Our days are filled with more than just that. We have a purpose in what we do at Thermo Fisher Scientific. Our work demands passion and produces worthwhile results. We do important work. Customers benefit from our knowledge and technological advancements as we work with them to improve the world, whether by finding a cancer cure, preserving the environment, or ensuring the safety of our food.

Also, Bio-Synthesis Inc. High-quality nucleic acids, peptides, and other molecular biology products are produced by the biology contract manufacturer Bio-synthesis for the research, diagnostic, and therapeutic industries. Bio-Synthesis adheres to GLP and GMP regulations and is ISO 90012015 certified. Our solutions aid in the advancement of biomedical research and drug development. Privately owned and based in Lewisville, Texas, Bio-Synthesis was established in 1984.

Key Companies in the Oligonucleotide Synthesis market include

• Medtronic Inc (Ireland)


• Abbott Laboratories (US)


• Stryker Corporation (US)


• DePuy Synthes (US)


• Braun Melsungen AG (Germany)


• NuVasive, Inc (US)


• Zimmer Biomet (US)


• Orthofix (US)


• Globus Medical (US), among others

Oligonucleotide Synthesis Industry Developments

September 2020 The DIA/FDA Oligonucleotide-based Therapeutics Conference was held in North Bethesda and covered topics such as quality risk management, manufacturing advancements, specifications, formulation issues, oligonucleotide pharmacokinetics, nonclinical assessments in support of drug development, clinical advances in therapeutic targets, trial design, and safety for antisense, siRNA, mRNA, and microRNA therapies. Providing information on the therapeutic uses of oligonucleotides, the 14th annual meeting of the Oligonucleotide Therapeutics Society was held in Seattle.

Oligonucleotide Synthesis Market Segmentation

Oligonucleotide Synthesis Products Outlook

• Oligonucleotide


• Reagents and Equipment

Oligonucleotide Synthesis Type Outlook

• Custom Oligos


• Predesigned Oligos

Oligonucleotide Synthesis Applications Outlook

• Therapeutic Applications


• Diagnostics


• Research


• Others

Oligonucleotide Synthesis End User Outlook

• Orthopedic Clinics


• Multispecialty Hospitals


• Neurology Clinics


• Others

Oligonucleotide Synthesis Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America